Optimization of blood pressure measurement practices for pharmacodynamic analyses of tyrosine‐kinase inhibitors

Optimization of blood pressure measurement practices for pharmacodynamic analyses of tyrosine‐kinase inhibitors

Abstract Blood pressure measurements form a critical component of adverse event monitoring for tyrosine kinase inhibitors, but might also serve as a biomarker for dose titrations. This study explored the impact of various sources of within‐individual variation on blood pressure readings to improve m...

Полное описание

Библиографические подробности
Главные авторы:	Maddalena Centanni, Abel Thijs, Ingrid Desar, Mats O. Karlsson, Lena E. Friberg
Формат:	Статья
Язык:	English
Опубликовано:	Wiley 2023-01-01
Серии:	Clinical and Translational Science
Online-ссылка:	https://doi.org/10.1111/cts.13423

Схожие документы

Model-Based Biomarker Selection for Dose Individualization of Tyrosine-Kinase Inhibitors
по: Maddalena Centanni, и др.
Опубликовано: (2020-03-01)

Assessment of ibrutinib scheduling on leukocyte, lymph node size and blood pressure dynamics in chronic lymphocytic leukemia through pharmacokinetic‐pharmacodynamic models
по: Eman I. K. Ibrahim, и др.
Опубликовано: (2023-09-01)

Increase in Blood Pressure Associated With Tyrosine Kinase Inhibitors Targeting Vascular Endothelial Growth Factor
по: Sarah Waliany, MD, MS, и др.
Опубликовано: (2019-09-01)

TYROSINE KINASE INHIBITORS AND INTERFERON
по: Maria Dimou, и др.
Опубликовано: (2014-01-01)

TYROSINE KINASE INHIBITORS AND PREGNANCY
по: Elisabetta Abruzzese, и др.
Опубликовано: (2014-04-01)

Therapeutic Drug Monitoring of Tyrosine Kinase Inhibitors Using Dried Blood Microsamples
по: Nick Verougstraete, и др.
Опубликовано: (2022-03-01)

Receptor Tyrosine Kinases and Inhibitors in Lung Cancer
по: Evan Pisick, и др.
Опубликовано: (2004-01-01)

Inhibition of c-Kit by tyrosine kinase inhibitors
по: Allison Galanis, и др.
Опубликовано: (2015-03-01)

Tyrosine kinase inhibitor Tofacitinib. Safety issues
по: G. V. Lukina, и др.
Опубликовано: (2015-12-01)

Tyrosine Kinase Inhibitors Target B Lymphocytes
по: Nikki Lyn Esnardo Upfold, и др.
Опубликовано: (2023-02-01)

Spheroacanthocytes secondary to novel tyrosine kinase inhibitors
по: Michael Ashby, и др.
Опубликовано: (2020-11-01)

Second-generation inhibitors of Bruton tyrosine kinase
по: Jingjing Wu, и др.
Опубликовано: (2016-09-01)

Targeting tumour microenvironment by tyrosine kinase inhibitor
по: Hor-Yue Tan, и др.
Опубликовано: (2018-02-01)

Mechanisms of resistance to EGFR tyrosine kinase inhibitors
по: Lihua Huang, и др.
Опубликовано: (2015-09-01)

Mechanisms of acquired resistance to tyrosine kinase inhibitors
по: Yi-fan Chen, и др.
Опубликовано: (2011-12-01)

Tyrosine Kinase Inhibitors in Pulmonary Vascular Disease
по: John J. Ryan, MD
Опубликовано: (2016-12-01)

Mutations in the MET tyrosine kinase domain and resistance to tyrosine kinase inhibitors in non-small-cell lung cancer
по: Yu Yao, и др.
Опубликовано: (2023-01-01)

The two facets of receptor tyrosine kinase in cardiovascular calcification—can tyrosine kinase inhibitors benefit cardiovascular system?
по: Ainun Nizar Masbuchin, и др.
Опубликовано: (2022-09-01)

Characterization of acquired receptor tyrosine–kinase fusions as mechanisms of resistance to EGFR tyrosine–kinase inhibitors
по: Xu H, и др.
Опубликовано: (2019-07-01)

Transarterial Chemoembolization Combined with Immune Checkpoint Inhibitors Plus Tyrosine Kinase Inhibitors versus Immune Checkpoint Inhibitors Plus Tyrosine Kinase Inhibitors for Advanced Hepatocellular Carcinoma
по: Huang JT, и др.
Опубликовано: (2022-11-01)

Novel Approaches for Efficient Delivery of Tyrosine Kinase Inhibitors
по: Zahra Moradpour, и др.
Опубликовано: (2019-01-01)

Advances in MET tyrosine kinase inhibitors in gastric cancer
по: Yifan Zhang, и др.
Опубликовано: (2024-06-01)

Mechanism and treatment of diarrhea associated with tyrosine kinase inhibitors
по: Jiangnan Liu, и др.
Опубликовано: (2024-03-01)

The Use of Bruton Tyrosine Kinase Inhibitors in Waldenström’s Macroglobulinemia
по: Obada Ababneh, и др.
Опубликовано: (2022-05-01)

Tyrosine kinase inhibitors in osteosarcoma: Adapting treatment strategiesa
по: Ahmad Assi, и др.
Опубликовано: (2023-12-01)

Structural Insight and Development of EGFR Tyrosine Kinase Inhibitors
по: Tasia Amelia, и др.
Опубликовано: (2022-01-01)

Flavonoids as receptor tyrosine kinase inhibitors in lung cancer
по: Sareshma Sudhesh Dev, и др.
Опубликовано: (2023-11-01)

Tyrosine kinase inhibitors, ionic currents, and cardiac arrhythmia
по: Chi-Hao Hu, и др.
Опубликовано: (2023-07-01)

Pulmonary hypertension with dasatinib and other tyrosine kinase inhibitors
по: Ashraf El-Dabh, и др.
Опубликовано: (2019-07-01)

Advances in studies of tyrosine kinase inhibitors and their acquired resistance
по: Qinlian Jiao, и др.
Опубликовано: (2018-02-01)

Tyrosine Kinase Inhibitors - Induced Cutaneous Leukocytoclastic Vasculitis
по: Diogo Alpuim Costa, и др.
Опубликовано: (2018-05-01)

Tyrosine Kinase Inhibitor Induced Isolated Pericardial Effusion
по: Vineet Agrawal, и др.
Опубликовано: (2015-02-01)

Acquired Resistance Mechanism for MET Tyrosine Kinase Inhibitor
по: Toshio Fujino, MD, и др.
Опубликовано: (2021-03-01)

Exploring receptor tyrosine kinases-inhibitors in Cancer treatments
по: D. Samuel Metibemu, и др.
Опубликовано: (2019-12-01)

The Lysosomal Sequestration of Tyrosine Kinase Inhibitors and Drug Resistance
по: Eliska Ruzickova, и др.
Опубликовано: (2019-10-01)

Small molecule tyrosine kinase inhibitors in pancreatic cancer
по: Sachin Gupta, и др.
Опубликовано: (2008-10-01)

Tyrosine Kinase Inhibitors as Antiangiogenic Drugs in Multiple Myeloma
по: Domenico Ribatti
Опубликовано: (2010-04-01)

A Review on Newer Tyrosine Kinase Inhibitors and their Uses
по: NITHU M KUMAR, и др.
Опубликовано: (2018-08-01)

Resistant Mechanism and Treatment Strategy of Tyrosine Kinase Inhibitors
по: Jianbing QIAO, и др.
Опубликовано: (2011-10-01)

Editorial: New Insights on Bruton’s Tyrosine Kinase Inhibitors
по: C. I. Edvard Smith, и др.
Опубликовано: (2021-11-01)